Skip to Content
Merck

D1010000

Dibutyl phthalate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

n-Butyl phthalate, DBP, Phthalic acid dibutyl ester

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Linear Formula:
C6H4-1,2-[CO2(CH2)3CH3]2
CAS Number:
84-74-2
Molecular Weight:
278.34
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329798660
MDL number:
MFCD00009441
Beilstein/REAXYS Number:
1914064

Product Name

Dibutyl phthalate, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3

SMILES string

CCCCOC(=O)c1ccccc1C(=O)OCCCC

InChI key

DOIRQSBPFJWKBE-UHFFFAOYSA-N

grade

pharmaceutical primary standard

vapor density

9.6 (vs air)

vapor pressure

1 mmHg ( 147 °C)

API family

dibutyl phthalate

autoignition temp.

756 °F

expl. lim.

0.47 %, 236 °F

manufacturer/tradename

EDQM

refractive index

n20/D 1.492 (lit.)

bp

340 °C (lit.)

mp

−35 °C (lit.)

density

1.043 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Plasticizer

General description

This compound is listed in the SVHC (Substances of very high concern) candidate list of ECHA (European Chemicals Agency)
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

367.7 °F - open cup

flash_point_c

186.5 °C - open cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
J W Chang et al.
Environmental pollution (Barking, Essex : 1987), 189, 77-84 (2014-03-19)
Phthalates strongly and adversely affect reproduction, development and liver function. We did a cumulative risk assessment for simultaneous exposure to nine phthalates using the hazard index (HI) and the levels of nine phthalates in 1200 foodstuff samples. DEHP (di-2-ethylhexyl phthalate)
Yuichiro Yano et al.
Journal of the American College of Cardiology, 65(4), 327-335 (2015-01-31)
Isolated systolic hypertension (ISH), defined as systolic blood pressure (SBP) ≥140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg, in younger and middle-aged adults is increasing in prevalence. The aim of this study was to assess the risk
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service